Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

Mon, 08th Feb 2021 10:46

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Omega Diagnostics, up 40% at 96.98 pence, 12-month range 5.93p-126.95p. It will continue to modify its Alva-based facility to "upscale significantly" its lateral flow test production capacity as it noted a Financial Times article. The FT said the UK government has chosen three British companies to make rapid Covid-19 tests. The newspaper said Omega, SureScreen and Global Access Diagnostics have been selected by the Department of Health to produce up to 2 million lateral flow devices per day for the UK, according to two people briefed on the decision.

----------

Avacta Group, up 6.8% at 136.20 pence, 12-month range 13.00p-215.25p. Says it has entered into a commercial partnership with Mologic to accelerate to market Avacta's AffiDX SARS-CoV-2 lateral flow rapid antigen test. The pre-clinical stage biotechnology company said the partnership will provide the AffiDX antigen test a faster route to market by giving it a CE marking for professional use under rapid diagnostics firm Mologic's ISO13485 quality system.

----------

Tower Resources, up 11% at 0.56 pence, 12-month range 0.189p-0.650p. Notes its South African unit Rift Petroleum has received an updated resource at the offshore Algoa-Gamtoos license from partner New Age Energy Algoa. After reprocessing seismic data at the asset, overall portfolio volumes are 54% higher at Algoa-Gamtoos, Tower explained.

----------

AIM - LOSERS

----------

Bahamas Petroleum, down 67% at 0.68p, 12-month range 0.500p-5.722p. Bahamas said that while the Perseverance #1 well encountered hydrocarbons, commercial volumes of oil were not proven. The company said the Perseverance #1 well in the Bahamas encountered hydrocarbons, as well as successfully validating the structural model and the petroleum system. However, volumes of oil encountered "are not commercial".

----------

Tissue Regenix, down 12% at 0.65p, 12-month range 0.275p-1.280p. The company expects a revenue fall in 2020, citing the negative impact of the Covid-19 pandemic. The medical devices company expects revenue of GBP12.8 million, down 1.5% from 2019's GBP13.0 million. Its financial performance was "impacted by the ongoing coronavirus pandemic".

----------

Inland Homes, down 10% at 57.75p, 12-month range 32.00p-89.85p. The company reported a fall in full-year profit as activity was disrupted by the coronavirus pandemic. Its EPRA net asset value per share at the end of September 2020 was 103.97 pence per share, down 8.5% on a year ago due to a placing of 20.8 million new shares during the year. In a separate release, Inland Homes said Chair Terry Roydon will be standing down from the board at the conclusion of the company's annual general meeting in March. Senior Independent Director Simon Bennett will be promoted to chair,

----------

boohoo Group, down 4.5% at 348.40p, 12-month range 133.10p-433.50p. The AIM-listed online-only fashion retailer will be buying the e-commerce and digital assets and associated intellectual property rights, including customer data, related business information and inventory, of the Burton, Dorothy Perkins and Wallis brands. The GBP25.2 million deal to acquire the former Arcadia Group brands does not include any stores. boohoo said Monday's acquisition is a "significant opportunity to grow" its market share.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
8 Mar 2021 11:06

Avacta confirms efficacy of test on variant Covid-19 strains

(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.

Read more
24 Feb 2021 11:45

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

Read more
24 Feb 2021 10:25

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

Read more
22 Feb 2021 11:01

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

Read more
22 Feb 2021 09:28

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

Read more
22 Feb 2021 08:54

Avacta clarifies reports on potential use of its Covid-19 test

(Sharecast News) - Avacta Group responded to some press speculation on take-up of its lateral flow SARS-CoV-2 rapid antigen test for Covid-19 by the UK government on Monday.

Read more
22 Feb 2021 08:47

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

Read more
18 Feb 2021 14:31

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

Read more
18 Feb 2021 08:49

Avacta gets approval for first-in-human study of AVA6000

(Sharecast News) - Biotherapeutics and reagents developer Avacta has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for a phase 1 study of its lead 'preCISION' pro-drug, AVA6000 pro-doxorubicin, it announced on Thursday.

Read more
16 Feb 2021 11:31

AIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut

AIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut

Read more
16 Feb 2021 09:48

Avacta Shares Surge On Positive Data For Covid-19 Antigen Test

Avacta Shares Surge On Positive Data For Covid-19 Antigen Test

Read more
16 Feb 2021 09:38

Avacta upbeat on initial data for Covid-19 rapid test study

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK, it announced on Tuesday.

Read more
8 Feb 2021 11:25

Avacta enters commercial partnership with Mologic

(Sharecast News) - Biotherapeutics developer Avacta Group has entered into a commercial partnership with Mologic, it announced on Monday, to accelerate to market its 'AffiDX' SARS-CoV-2 lateral flow rapid antigen test.

Read more
8 Feb 2021 09:37

Avacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test

Avacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.